Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6923959

Title:Method of pre-inducing a state of immune tolerance before organ transplantation
Inventors:Habener, Joel F.; Newton Centre, MA, USA
Summary:Described herein is a method of treating a patient suffering from diabetes mellitus by isolating a nestin- or ABCG2-positive pancreatic stem cell from a pancreatic islet of a donor, and transferring the stem cell into the patient. The invention relates to methods and compositions for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Also described are properties of nestin which has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Further disclosed are methods by which nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain additional stem cells or pseudo-islet like structures. Methods are included for the ex vivo differentiation of the pancreatic stem cells, as are methods by which pancreatic stem cells can be expanded and transplanted into a patient in need of such therapy, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Abstract:Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6923959
Application Number:US2002000136891
Date Filed:02/05/2002
Date Published:02/08/2005
Assignee:The General Hospital Corporation, Boston, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/13/2020